Neurocentrx is seeking the 1st FDA approval of an abuse-deterrent oral ketamine therapy for depression suitable for clinical and home administration. The company is Phase 3 ready, with a patent abuse-deterrent capsule formulation that may be suitable for 505(b)(2) accelerated approval. The company is seeking $15M to fund Phase 2 proof-of-concept trials, which will demonstrate efficacy in treatment-resistant major depression, and a care pathway featuring clinically supervised bridging of treatment into home settings. The company works with leading psychiatrists at Kings College London and McLean / MGH hospitals. Once approved, our innovative oral ketamine care option can replace expensive and complex ketamine treatments currently used to treat severe depression. We have received investment from UK seed investors, the Scottish Enterprise Fund and the Wellcome Trust.